This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Musson, D. G.
Right arrow Articles by Rogers, J. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Musson, D. G.
Right arrow Articles by Rogers, J. D.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, May 2003, p. 1732-1735, Vol. 47, No. 5
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.5.1732-1735.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Pharmacokinetics of Intramuscularly Administered Ertapenem

Donald G. Musson,1* Anup Majumdar,1 Kimberly Birk,1 Sherry Holland,1 Peter Wickersham,1 Susan X. Li,1 Goutam Mistry,1 Alison Fisher,1 Scott Waldman,2 Howard Greenberg,2 Paul Deutsch,1 and J. Douglas Rogers1

Merck Research Laboratories, West Point, Pennsylvania 19486,1 Thomas Jefferson University Hospital, Philadelphia, Pennsylvania 191072

Received 21 June 2002/ Returned for modification 4 November 2002/ Accepted 4 February 2003

Ertapenem (INVANZ) is a new once-a-day parental ß-lactam antimicrobial agent that has been shown to be highly effective as a single agent for treatment of various community-acquired and mixed infections. The plasma pharmacokinetics of a 1-g intramuscular (i.m.) dose was compared with those of a 1-g intravenous (i.v.) dose infused over 30 min, the recommended rate of i.v. infusion for comparison, and over 120 min, which more closely mimicked the time course for absorption of the i.m. form. In a three-period crossover study (Part A), 26 healthy subjects received single doses of ertapenem administered i.m., i.v. infused over 30 min, and i.v. infused over 120 min. Blood for ertapenem analysis was collected over 24 h postdose for each treatment. In Part B, these fasted subjects received a 1-g i.m. dose of ertapenem once daily for 7 days. Following a 1-g i.m. dose and a 1-g i.v. dose infused over 120 min, the geometric mean area under the concentration curve from hour 0 to infinity (AUC0-{infty}) was 541.8 µg · hr/ml following i.m. administration and 591.4 µg · hr/ml following a 120-min infusion; the geometric mean ratio was 0.92 with a 90% confidence interval of 0.88 to 0.95. The geometric mean AUC0-{infty} was nearly identical when 1-g doses were infused over 30 or 120 min. Although the maximum concentration of drug in serum was somewhat lower following i.m. administration than following i.v. administration, the shape of the plasma concentration profiles was roughly comparable at later time points. Ertapenem did not accumulate after multiple 1-g i.m. daily doses over 7 days. The geometric mean ratio for AUC0-24 (day 7/day 1) was 0.98 with a 90% confidence interval of 0.94 to 1.02. Thus, the relative bioavailability of the 1-g i.m. dose was 92%. Ertapenem does not accumulate following multiple daily 1-g i.m. doses over 7 days.

* Corresponding author. Mailing address: Merck Research Laboratories, Sumneytown Pike, West Point, PA 19486. Phone: (215) 652-8480. Fax: (215) 652-4524. E-mail: don_musson{at}merck.com.

Antimicrobial Agents and Chemotherapy, May 2003, p. 1732-1735, Vol. 47, No. 5
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.5.1732-1735.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»